Printer Friendly

Spectrum of gastroenteropancreatic NENs in routine histological examinations of bioptic and surgical specimen: a study of 161 cases collected from 17 departments of pathology in the Czech Republic.

1. Introduction

Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) represent a group of tumours of increased clinical significance [1, 2]. Recently, updated guidelines for the management of patients with digestive neuroendocrine tumours and current diagnostic procedure have been published [3, 4]. One of the essential components of the diagnostic protocol is bioptic examination that enables establishing histopathologic typing, grading, and staging of individual tumours [5]. A standardized pathology report is the need for adequate management of patients [6]. Frequency of GEP-NENs, their appearance within the GIT, and the spectrum of their histologic types are to some extent different in individual countries [7-14]. The aim of this study was to collect the cases of GEP-NENs from different departments of pathology in the Czech Republic, characterize the spectrum of GEPNENs diagnosed in these departments in two-year period from 2007/01/01 to 2008/12/31, analyse the data obtained from bioptic reports, and evaluate how newly formulated WHO classification (2010) [15] is acceptable in regular (common) diagnostic practice.

2. Materials and Methods

All tumours diagnosed as carcinoids, neuroendocrine tumours, or neuroendocrine carcinomas in two-year period from 2007/01/01 to 2008/12/31 in 17 different departments of pathology represented by 5 university hospitals and 12 regional hospitals and laboratories were included into the study. These departments were randomly selected from total of 96 departments of pathology within the whole Czech Republic. The day of inclusion was the day of pathological report. Paraffin-embedded tissue blocks and bioptic reports from participating departments were collected at the Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital King's Vineyards, Prague, Czech Republic. Five-micron-thick paraffin sections were prepared from all collected blocks and stained with routine hematoxylin and eosin and by immunohistochemistry to detect chromogranin A (CgA), synaptophysin, and Ki-67. All antibodies used for immunohistochemistry were purchased from DakoCytomation (Glostrup, Denmark). Polyclonal rabbit anti-CgA was diluted 1: 600, monoclonal anti-synaptophysin (clone SY 38) was diluted 1: 20, and monoclonal anti-Ki-67 (clone MIB-1) was diluted 1:50. Histofine detection system (Exbio, Czech Republic) and 3-3' diaminobenzidine as a chromogen were used to visualize immunohistologic reaction. The slides were evaluated independently by two pathologists specialized in NEN diagnostics (Vaclav Mandys and Tomas Jirasek) under an optical microscope. Presented diagnostic conclusions are based on consequent consensus.

3. Results

Overall information on the number of tumours in individual sites, age of patients, and source of tissue samples are summarized in Table 1.

Histologic classification of tumours is summarized in Table 2.

Distribution of tumours according to histologic type is introduced in Figure 1.

3.1. Stomach. In 29 cases from stomach, endoscopic biopsies predominated (26 blocks). In 2 cases only, tissue blocks were obtained from surgical resection. Neuroendocrine tumours (NETs) predominated in this group (27 cases). In one case only the tumour was classified as neuroendocrine carcinoma (small cell carcinoma). In one case the tumour was reclassified as nonneuroendocrine carcinoma, probably metastatic, from anamnestically preexisting breast carcinoma of nonspecified histologic type. Detection of CgA and synaptophysin was positive in all NETs in most cells. In the case of small cell carcinoma, immunoreactivity for CgA and synaptophysin was evident only focally. In the tumour finally diagnosed as metastatic carcinoma, immunodetection of CgA was negative and synaptophysin was detected small number of tumour cells only. Grading of NENs was as follows: NET G1 22 cases, NET G2 5 cases, NEC G3 1 case. Other changes observed in evaluated slides were represented by chronic atrophic gastritis (19 cases). In 1 patient the history of metachronous gastric carcinoma was noted.

3.2. Duodenum. In 10 patients with duodenal tumours predominated endoscopic biopsies (8 cases), 2 patients underwent resection. All tumours were classified as NETs G1. All tumours showed strong immunostaining for CgA and synaptophysin in the majority of neoplastic cells and displayed very low proliferative activity corresponding with G1 (Ki-67 index [less than or equal to] 2). In one case, evaluation of Ki-67 index was difficult due to limited extent of tissue samples. In one case anamnestic data on synchronous gastrointestinal stromal tumour (GIST) in the small intestine were introduced in the bioptic report.

3.3. Jejunum and Ileum. In 20 patients (out of all 28 cases), the primary site of tumour was ileum, in 1 patient jejunum, and in remaining 7 cases the site was introduced as small intestine, not otherwise specified. Resection specimens were obtained from 24 patients; endoscopic biopsies were in 4 cases only. Tumours were classified as NET G1 in 23 cases and NET G2 in 2 cases. One neoplasm was classified as NEC G3, a small cell type and one case as mixed adenoneuroendocrine carcinoma (MANEC). Remaining tumour was re-classified as poorly differentiated adenocarcinoma.

In all NETs strong immunoreactivity for CgA and synaptophysin was detected in the vast majority of cells. In 3 cases, diagnosis of carcinoma was established. One of them was small cell NEC, with only focal expression of CgA and synaptophysin and with high proliferative activity of tumour cells (Ki-67 index exceeding 50%), corresponding with G3. One case was diagnosed as MANEC, expressing CgA and synaptophysin, tumour grade G3. The last case, originally diagnosed as "carcinoid" was re-classified as poorly differentiated adenocarcinoma, without signs of neuroendocrine differentiation.

3.4. Appendix. All 42 appendiceal tumours were "incidentalomas". Appendectomy was performed predominantly due to appendicitis (37 cases). In 2 cases, appendectomy was performed during the surgery for colorectal adenocarcinoma, in 1 case for ovarian carcinoma, in 1 case for cervical carcinoma, and in 1 case for endometrial carcinoma. In all cases, resection specimen was evaluated. NETs G1 predominated in this group (39 cases). Goblet cell carcinoid was diagnosed in 2 cases with predominating neoplastic infiltration of submucosa in one of them and with more extensive infiltration of tunica muscularis in the second tumour. Remaining one case was diagnosed as MANEC with broad neoplastic infiltration of tunica muscularis. All NETs displayed strong immunoreactivity for CgA and synaptophysin in almost all neoplastic cells. In all cases of goblet cell carcinoid/MANEC, CgA and synaptophysin were present only in scattered neoplastic cells. Ki-67 index was [less than or equal to] 2 in all NETs and up to 3% in goblet cell carcinoids. In MANEC, the Ki-67 index exceeded 30%.

3.5. Large Intestine. Out of 40 tumours located in the large intestine, 21 cases were in rectum, 1 in sigmoid colon, 2 in caecum, and 1 in ascending colon, and in 15 remaining cases, exact location of a tumour was not introduced in the bioptic report. In 30 patients endoscopic biopsies were available, and resection specimens were evaluated in 10 cases. NET G1 was classified in 30 cases and there were 3 NETs G2; one case was classified as NEC, small cell type. Remaining 6 tumours were re-classified as poorly differentiated adenocarcinomas. In one patient with NET G1, two synchronous colonic adenocarcinomas were described within the resection specimen. In all cases of NETs, strong expression of CgA and synaptophysin was detected. In the case of small cell carcinoma, immunohistological detection of CgA was negative, synaptophysin was focally positive and proliferative activity of tumour cells (Ki-67 index) was higher than 80%. In remaining 6 cases, tumours were re-classified as poorly differentiated adenocarcinomas. These tumours were either completely negative for neuroendocrine markers, or showed markers of neuroendocrine differentiation in scattered neoplastic cells only.

3.6. Pancreas. Resection specimens were available in all 12 cases. No anatomical sublocation of the tumour within the pancreas was introduced in all these tumours. Previous endoscopic biopsy in one patient with NET G1 was also available. Seven tumours were classified as NETs G1, and 3 tumours were NETs G2. Two tumours were neuroendocrine carcinomas (NEC), one of them of small cell type and the second one a large cell NEC. All G1/G2 tumours displayed strong immunoreactivity for CgA and synaptophysin. Both NECs were immunohistologically positive for synaptophysin, while immunodetection of chromogranin-A was negative in a small cell tumour. Proliferative activity (Ki-67 index) corresponded with tumour grades.

4. Discussion

Extended knowledge and increased clinical interest in neuroendocrine neoplasms urged the effort to formulate a new classification of these tumours. Definitions of individual tumour types introduced in the WHO Classification published in 2000 [16] and consequently refined especially by ENETS [9, 17-20] represented a new approach to classify NENs using not only pure histomorphologic criteria, but also clinicopathological correlation. Distinction of well-differentiated neuroendocrine tumour classified as potentially malignant from well-differentiated neuroendocrine carcinoma assessed as low-grade malignant was not based on the histological appearance of the tumour, but biologic behaviour of the tumour was estimated by the tumour size and extension. Despite of the progress, such approach appeared to some extent problematic in cases where endoscopic biopsies were available only.

Recently, a new WHO classification of tumours of the digestive tract (2010) introduces simplified categorisation of NENs [15]. The most substantial advantage of this new classification is definition of 4 essential tumour types, based on histomorphologic appearance and proliferative activity of tumour cells (Ki-67 index). Clear definition of these tumour categories (NET G1, NET G2, NEC, and MANEC) in all locations of the digestive tract eliminates diagnostic problems in endoscopically obtained small tissue samples.

The major change in the new WHO classification (2010) [15] is a new approach in coding of NENs according to ICDO3. All 4 essential tumour types are coded in all locations as malignant (/3), with two exceptions only. This approach significantly differs from the WHO classification 2000 [16], where tumours of small size, low proliferative and mitotic activity, and displaying limited progression were classified as tumours of "benign" or "uncertain" behaviour and coded according to ICD-O3 as tumours of uncertain behaviour (/1).

Data on incidence of NEN and on their frequency in individual sites of origin within the GIT have been published in more studies. However, some of these data are to some extent controversial. Appendix as the most frequent site of NENs was observed not only in our study, but also in identical finding published by others [9,14]. High frequency of NENs has also been described in the colon and rectum [10-12] and in the small intestine [7, 8]. More exceptionally, stomach has been mentioned as the main site of GEP-NENs [13]. Relatively higher number of appendiceal incidentalomas in our study could be explained by a fact that detailed bioptic examination of appendices has been still mandatory in the Czech Republic.

This study cannot contribute to evaluation of incidence of GEP-NENs in the Czech Republic. The data from Central Oncological Registry of the Czech Republic indicate the incidence approximately 4/100 000/year.

From the clinical point of view and to select the adequate therapeutic strategy it is necessary to estimate the risks of aggressive behaviour of the particular tumour. Apart from the tumour type, grade, and stage, location of the tumour plays an important role in this estimation. The need to classify the particular tumour precisely is evident. Our study demonstrates that before introduction of WHO 2010 classification the majority of tumours in original bioptic reports were classified as "carcinoids" (19 of 29 in stomach; 6 of 10 in duodenum; 14 of 28 in the small intestine; 23 of 42 in appendix; 23 of 40 in the large bowel). Approximately 1/3 of GIT tumours (52) and 11 of 12 pancreatic tumours were classified in accordance with the WHO 2000 Classification as well-differentiated neuroendocrine tumours or well-differentiated neuroendocrine carcinomas. Major diagnostic discordancy was found in 10 cases. Six of these tumours represented undifferentiated carcinomas of the large bowel which were originally diagnosed 3x as MANEC, 2x as malignant carcinoid, and 1x as neuroendocrine carcinoma. One poorly differentiated carcinoma of jejunum was originally diagnosed as carcinoid. Small cell carcinomas, 1 in stomach and 1 in ileum, were originally classified as malignant carcinoid and carcinoid, respectively. One gastric tumour originally diagnosed as carcinoid was re-classified as non-neuroendocrine carcinoma, probably metastasis of breast cancer.

In our opinion, diagnostic process of NENs should be performed in close cooperation with the clinicians, especially oncologists. Biphasic diagnostic procedure of NENs is recommended in our conditions (the Czech Republic). The first (essential) diagnosis of a NEN is performed in all departments of pathology. Consequently, usually based on the clinician request, extended and more detailed diagnosis, including detection of wider spectrum of tumour markers, like hormonal products, is performed in specialized centres by the "second opinion". Such approach contributes to improvement of diagnostic procedure especially in rare challenging cases and in patients with unusual clinical symptomatology.

5. Conclusions

The results of our study demonstrate the frequency of individual types of GEP-NENs in routine bioptic examinations and appearance of NENs in different sites of origin within the GIT. We demonstrate slight differences in primary sites of GEP-NENs in our region, comparing to other countries. Relatively higher number of appendiceal incidentalomas in our study could be explained by a fact that detailed bioptic examination of appendices has been still mandatory in the Czech Republic. Our study gave evidence that the WHO 2010 classification of NENs represents fully acceptable approach for histopathologic diagnosis and enables categorising the tumours without difficulties.

http://dx.doi.org/ 10.1155/2014/373828

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This work was supported by a grant awarded from Novartis Oncology and by the research Project PRVOUK-Oncology P27, awarded by the Charles University in Prague. The authors thank all contributing pathologists who provided paraffin blocks and biopsy reports: Kamila Benkova, Department of Pathology, Hospital Na Bulovce, Prague, Czech Republic; Antonin Bluml, Department of Pathology, Regional Hospital Liberec, Czech Republic; Martin (Began, CGB Laboratory, Ostrava, Czech Republic; Tomas Cizek, Department of Pathology, Regional Hospital Svitavy, Czech Republic; Ondrej Daum, Sikl's Department of Pathology, Faculty of Medicine and University Hospital, Plzenz, Czech Republic; Sona Fejtova, Department of Pathology, Regional Hospital Havlickuv Brod, Czech Republic; Jan Gumanak, P+R Lab, Novy Jicin, Czech Republic; Maria Hacova, Department of Pathology, Regional Hospital Pardubice, Czech Republic; Vladimir Horava jr., Biocytolab, Frydek-Mistek Czech Republic; Michal Kheck, Department of Pathology, Regional Hospital Jihlava, Czech Republic; Roman Kodet, Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic; Karel Pelikaan, Department of Pathology, Regional Hospital Jindfichuv Hradec, Czech Republic; Marie Rydlova, Department of Pathology, Regional Hospital Havifov, Czech Republic; AleS Ryska, Fingerland's Department of Pathology, Faculty of Medicine and University Hospital, Hradec Kralova, Czech Republic; Vladimir Straka Department of Pathology, Regional Hospital Nachod, Czech Republic; and Martin Tichy, Department of Pathology, University Hospital Olomouc, Czech Republic.

References

[1] S. Schimmack, B. Svejda, B. Lawrence, M. Kidd, and I. M. Modlin, "The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors," Langenbeck's Archives of Surgery, vol. 396, no. 3, pp. 273-298, 2011.

[2] A. Frilling, G. Akerstrom, M. Falconi et al., "Neuroendocrine tumor disease: an evolving landscape," Endocrine-Related Cancer, vol. 19, no. 5, pp. 163-185, 2012.

[3] R. Salazar, B. Wiedenmann, G. Rindi, and P. Ruszniewski, "ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update," Neuroendocrinology, vol. 95, no. 2, pp. 71-73, 2012.

[4] P. Kuiper, H. W. Verspaget, L. I. H. Overbeek, I. Biemond, and C. B. Lamers, "An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach," Netherlands Journal of Medicine, vol. 69, no. 1, pp. 14-20, 2011.

[5] G. Kloppel, G. Rindi, A. Perren, P. Komminoth, and D. S. Klimstra, "The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement," Virchows Archiv, vol. 456, no. 6, pp. 595-597, 2010.

[6] M.-Y. Cho, J. H. Sohn, S. Y. Jin et al., "Proposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors: prognostic significance of pathological parameters," Korean Journal of Pathology, vol. 47, pp. 227-237, 2013.

[7] M. A. Maggard, J. B. O'Connell, and C. Y. Ko, "Updated population-based review of carcinoid tumors," Annals of Surgery, vol. 240, no. 1, pp. 117-122, 2004.

[8] I. M. Modlin, M. Kidd, I. Latich, M. N. Zikusoka, and M. D. Shapiro, "Current status of gastrointestinal carcinoids," Gastroenterology, vol. 128, no. 6, pp. 1717-1751, 2005.

[9] J. K. Ramage, A. H. G. Davies, J. Ardill et al., "Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours," Gut, vol. 54, supplement 4, pp. iv1-iv16, 2005.

[10] S. Chang, D. Choi, S. J. Lee et al., "Neuroendocrine neoplasms of the gastrointestinal tract: classification, pathologic basis, and imaging features," Radiographics, vol. 27, no. 6, pp. 1667-1679, 2007.

[11] T. Ito, H. Sasano, M. Tanaka et al., "Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan," Journal of Gastroenterology, vol. 45, no. 2, pp. 234-243, 2010.

[12] M. Y. Cho, J. M. Kim, J. H. Sohn et al., "Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors(GEP-NETs) in Korea 2000-2009: Multicenter study," Cancer Research and Treatment, vol. 44, no. 3, pp. 157-165, 2012.

[13] M. B. Niederle, M. Hackl, K. Kaserer, and B. Niederle, "Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters," Endocrine-Related Cancer, vol. 17, no. 4, pp. 909-918, 2010.

[14] E. Stoica-Mustafa, C. Pechianu, A. Iorgescu et al., "Pathological characteristics and clinical specifications in gastroenteropancreatic neuroendocrine tumors: a study of 68 cases," Romanian Journal of Morphology and Embryology, vol. 53, no. 2, pp. 351-355, 2012.

[15] F. T Bosman, F. Carneiro, R. H. Hruban, and N. D. Theise, Eds., WHO Clasification of Tumours of the Digestive System, IARC, 2010.

[16] E. Solcia, G. Kloppel, L. H. Sobin et al., Histological Typing of Endocrine Tumours, Springer, 2nd edition, 2000.

[17] C. Bordi, T. D'Adda, S. Pizzi, P. Crafa, and G. Rindi, "The assessment of malignancy in endocrine tumours of the gastrointestinal tract," Current Diagnostic Pathology, vol. 8, no. 6, pp. 421-429, 2002.

[18] G. Rindi and G. Kloppel, "Endocrine tumors of the gut and pancreas tumor biology and classification," Neuroendocrinology, vol. 80, supplement 1, pp. 12-15, 2004.

[19] U. Plockinger, G. Rindi, R. Arnold et al., "Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours: a consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)," Neuroendocrinology, vol. 80, no. 6, pp. 394-424, 2004.

[20] G. Klooppel, G. Rindi, M. Anlauf, A. Perren, and P. Komminoth, "Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors," Virchows Archiv, vol. 451, supplement 1, pp. S9-S27, 2007.

Vaclav Mandys and Tomas Jirasek

Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital King's Vineyards, Srobarova 50,100 34 Prague 10, Czech Republic

Correspondence should be addressed to Vaclav Mandys; vaclav.mandys@fnkv.cz

Received 15 October 2013; Revised 15 December 2013; Accepted 10 January 2014; Published 18 February 2014

Academic Editor: Anja Rinke

TABLE 1: Number of tumours in individual sites, age of patients, and
source of tissue samples.

Site                         Number of patients   Male : female ratio

Stomach                              29                  11:18
Duodenum                             10                   6:4
Jejunum and ileum                    28                 16 : 12
Appendix                             42                  11:31
Large intestine and rectum           40                 28 : 12
Pancreas                             12                   4:8
Total                               161                  76:85

Site                         Age: years (range)   Resection   Biopsy

Stomach                          66 (41-85)           2         27
Duodenum                         59(27-76)            2         8
Jejunum and ileum                65 (37-94)          24         4
Appendix                         38 (10-85)          42         0
Large intestine and rectum       42 (29-84)          10         30
Pancreas                         66 (44-79)          11         1
Total                            56 (10-94)          91         70

TABLE 2: Histologic classification of tumours with their number in
individual sites.

Site                         NET G1   NET G2   NEC    MANEC

Stomach                        22       5       1       0
Duodenum                       10       0       0       0
Jejunum and ileum              23       2       1       1
Appendix                       39       0       0       1
Large intestine and rectum     30       3       1       0
Pancreas                       7        3       2       0
Total                         131       13      5       2
%                            81.37     8.07    3.11   1.24

Site                         Goblet cell carcinoid   Other   Total

Stomach                                0               1      29
Duodenum                               0               0      10
Jejunum and ileum                      0               1      28
Appendix                               2               0      42
Large intestine and rectum             0               6      40
Pancreas                               0               0      12
Total                                  2               8      161
%                                    1.24            4.97     100
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article; neuroendocrine neoplasms
Author:Mandys, Vaclav; Jirasek, Tomas
Publication:Gastroenterology Research and Practice
Article Type:Report
Geographic Code:4EXCZ
Date:Jan 1, 2014
Words:3327
Previous Article:The effectiveness of self-expandable metallic stent insertion in treating right-sided colonic obstruction: a comparison between SEMS and...
Next Article:Endoscopic optical coherence tomography (OCT): advances in gastrointestinal imaging.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters